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Objective: To examine if statins have an effect on small nerve fibers.
Methods: This retrospective study evaluated the effect of statins in pure small-fiber
neuropathy (SFN). Outcome measures were symptom scales (numbness, tingling, and
autonomic symptoms), skin biopsies assessing epidermal nerve fiber density (ENFD),
sweat gland nerve fiber density (SGNFD), and quantitative autonomic testing.
Results: One hundred and sixty participants with pure SFN were identified.
Eighty participants (women/men, ageSD 33/47, 68.111.6 years old) were on
statins for 53.528.7months to treat dyslipidemia and they were age and
gender matched with 80 participants (33/47, 68.19.5) that were off statins.
ANOVA showed reduced ENFD/SGNFD at the proximal leg in the statin group
[(count/mm) 8.33.6/51.314.2] compared to the off statin group (10.43.8,
p=0.0008/56.412.7, p=0.018). There was no difference in ENFD/SGNFD at the
distal leg in the statin group (4.93.2/39.815.7) compared to the off statin group
(5.93.4, p=0.067/41.815.9, p=0.426). Statins did not affect symptom scales and
the outcome of autonomic testing.
Conclusion: Statin use is associated with degeneration of sensory and autonomic fibers.
The pattern of abnormalities, e.g., degeneration of proximal while sparing of distal fibers,
is consistent with a non-length-dependent process with lesions in the dorsal root and
the autonomic ganglia. The statin-associated sensory and autonomic ganglionopathy
is mild.
Keywords: statins, small-fiber neuropathy, ganglionopathy, neuronopathy, statin toxicity
Introduction
Statins, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are among
the most prescribed medications worldwide (Lewington et al., 2007). Statins lower cholesterol
levels, which can decrease the risk of cardiovascular and cerebrovascular disorders. Statins also
possess cholesterol-independent pleotrophic effects that include improved endothelium-dependent
Abbreviations: ENFD, epidermal nerve fiber density; FPP, farnesyl pyrophosphate; HMG-CoA, the 3-hydroxy-3-
methylglutaryl coenzyme A; QASAT, quantitative scale for grading of cardiovascular autonomic reflex tests and small fibers
from skin biopsies; SCOPA-AUT, the scales for outcomes in Parkinson’s disease-autonomic; SFN, small-fiber neuropathy;
SGNFD, sweat gland nerve fiber density.
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vasodilation, inflammation, lipid peroxidation, and oxidative
stress reduction (Willey and Elkind, 2010; Millar and Floras,
2014).
While the association of statins with liver (5–10%) and mus-
cle toxicity (<1% of statin users) is well defined, their associa-
tion with the function of the peripheral nervous system remains
incompletely understood (Gaist et al., 2002; Anderson et al., 2005;
Kiortsis et al., 2007; Argov, 2015). On rare occasions (1 case for
every 2200 statin patients-years), statins can induce large fiber
neuropathy that may be related to inhibition of ubiquinone, a key
mitochondrial respiratory chain enzyme (Kiortsis et al., 2007), or
to excessive depletion of cholesterol of nerve membranes (Gaist
et al., 2002). Knowledge about the association of statins with
small-fiber neuropathy (SFN) is limited. One report described
three patients in which statins were associated with sensory symp-
toms and abnormal sympathetic skin responses (Lo et al., 2003),
and another case-report described a patient with abnormal quan-
titative sudomotor reflex test (Boger et al., 2011). Both reports
attributed abnormal findings to statin-induced SFN. On the other
hand, statinsmay have beneficial effects on the peripheral nervous
system including small fibers since they may improve diabetic
polyneuropathy (Hernández-Ojeda et al., 2014) or autonomic
functions (Millar and Floras, 2014), presumably via pleotropic
effects.
The goal of this study was to analyze the long-term effect of
statins in patients with pure SFN.
Materials and Methods
Standard Protocol Approvals, Registrations, and
Patient Consents
The study was approved by the Institutional Review Board of the
University of Massachusetts Medical School.
Patient Selection
This was a retrospective single center study that included patients
who were referred for SFN evaluation at the Autonomic Labora-
tory, University of Massachusetts Medical School, between 2009
and 2015. All subjects were reviewed for symptoms and signs
suggestive of SFN from electronic case records.
Small-Fiber Neuropathy
Small-fiber neuropathy affects sensory and autonomic small fibers
resulting in a combination of sensory and autonomic symp-
toms (Novak et al., 2001; Devigili et al., 2008; Hovaguimian and
Gibbons, 2011). Typical sensory symptoms include distal limb
burning, prickling, stabbing discomfort, numbness or tingling.
SFN-associated autonomic symptoms include excessive coldness,
discoloration, erythromelalgia, hyper- or hypohydrosis, ortho-
static intolerance, and enteric or urinary symptoms (Novak et al.,
2001; Devigili et al., 2008). Multiple disorders are associated
with SFN including impaired glucose tolerance, metabolic syn-
drome, thyroid dysfunction, sarcoidosis, vitamin B12 deficiency,
HIV, neurotoxic medications including chemotherapeutic and
antiretroviral agents, celiac disease, paraneoplastic syndromes,
alcohol abuse, Sjogren syndrome, elevated triglycerides, and para-
proteinemias (McArthur et al., 1998; Novak et al., 2001; Low
et al., 2006; Devigili et al., 2008;Hovaguimian andGibbons, 2011).
In pure SFN which represent about 50% of all SFN cases, no cause
can be identified.
Symptom Scales
Sensory and autonomic assessments were done at an auto-
nomic laboratory. Sensory evaluations included self-reported
pain intensity using a 0–10 numerical rating scale that is
part of the NIH Toolbox (Cook et al., 2013) and numbness
or tingling scale using a 0–4 numerical grading (none–very
rare/mild–frequent–continuous). The Scale for Outcomes in
Parkinson’s Disease-Autonomic [SCOPA-AUT (Visser et al.,
2004)] has been used to evaluate autonomic symptoms. SCOPA-
AUT consists of 25 items assessing dysfunction in the gastroin-
testinal, urinary, cardiovascular, thermoregulatory, pupillomotor
and sexual domains. Each item is scored from 0 (no symptoms), 1
(rare), 2 (frequent) to 3 (severe).
Skin Biopsies
Skin biopsies were performed for the assessment of epidermal and
sweat gland nerve fibers. Skin biopsy can reliably demonstrate
loss of small epidermal fibers with a sensitivity and specificity
equal to 88 and 88.8%, respectively for the detection of SFN
(Devigili et al., 2008). Skin biopsies were performed following
the recommended standards (McArthur et al., 1998; Devigili
et al., 2008; Lauria et al., 2010; Hovaguimian and Gibbons, 2011).
Skin biopsies were obtained from the proximal thigh 20 cm dis-
tal to the iliac spine and at the calf (10 cm above the lateral
malleolus) using a 3-mm circular disposable punch tool. Sam-
ples were immediately transferred into 2% paraformaldehyde-
lysine-periodic acid fixative. Sample processing was done at
commercial laboratory in Therapath, New York, NY, USA.
Therapath is a CLIA-certified laboratory and is accredited by Col-
lege of American Pathologists. Samples were immunoperoxidase-
stained with the panaxonal marker PGP 9.5. Linear epidermal
nerve fiber density (ENFD) was obtained using bright light
microscopy following the guidelines of the European Federa-
tion of the Neurological Societies (Lauria et al., 2010). ENFD
was obtained in three or more sections and calculated as the
number of nerve fibers per length (density/mm) crossing the
dermal–epidermal junctions. Secondary branching was excluded
from the analysis. Sweat gland nerve fiber density (SGNFD) was
obtained from the same tissue sections also stained for PGP
9.5. Sweat glands were captured using an Olympus photomicro-
graph and analyzed according to the method described previ-
ously (Gibbons et al., 2009). All fiber counts were done by a
board certified neuropathologist that was blinded to the use of
statins.
Quantitative Autonomic Testing
All subjects referred for SFN underwent standardized autonomic
testing (Low et al., 2006; Novak, 2011) described in detail previ-
ously (Novak, 2011, 2015). Cardiovascular autonomic reflex tests
included deep breathing, the Valsalvamaneuver and tilt-table test.
Postganglionic sudomotor functions were assessed by quantitative
sudomotor axon reflex test (QSART) in the forearm, proximal
leg, distal leg, and foot, using the Q-Sweat machine (WRMedical
Electronics, Stillwater, MN, USA).
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Grading of Tests
The standardized functional cardiovascular reflex autonomic tests
(deep breathing, Valsalvamaneuver, and tilt test) and skin biopsies
(ENFD and SGNFD) were graded using Quantitative Scale for
Grading of Cardiovascular Autonomic Reflex Tests and Small
Fibers from Skin Biopsies (QASAT) (Novak, 2015). QASAT
grades cardiovascular tests, QSART, ENFD, and SGNFD.We used
QASAT-heart rate variability as a marker of cardiovagal activity
and QASAT-adrenergic failure (obtained as combination of the
Valsalvamaneuver and orthostatic hypotension score) as amarker
of sympathetic adrenergic failure. QASAT assigns a number to
each test result that is proportional to the severity of findings.
Normal test results correspond to 0, while abnormal results are
>0. Higher scores indicate more severe impairment. QASAT uses
age and gender adjusted normative data (if applicable) and scores
are generated automatically.
Definition of Pure SFN
The heterogeneity of SFN causes can mask the effect of statins,
therefore pure SFN was selected for this study. Available SFN
criteria use either sensory (Devigili et al., 2008) or autonomic
(Low et al., 2006) evaluations.
Devigili et al. (2008) defined SFN by combining signs sug-
gestive of SFN (pinprick and thermal sensory loss, allodynia,
and hyperalgesia) and reduced ENFD, the latter being the most
useful single test with a diagnostic efficiency of 88.4%. Low et al.
(2006) used abnormal sudomotor evaluations in SFN detection
with a sensitivity equal to 98%. Pure SFN affects both sensory
and autonomic fibers and therefore we defined pure SFN by the
combination of sensory and autonomic evaluations.
In this study, pure SFN was defined by the following crite-
ria: (1) presence of sensory and/or autonomic symptoms sug-
gestive of SFN; (2) QASAT score >0. An abnormality in any
single QASAT section will increase the score above 0 includ-
ing a single abnormality in EFND, SGFND, or any abnormal-
ity in cardiovascular autonomic functional testing; (3) all sec-
ondary causes of SFN have to be ruled out. Medical records
were screened for the following secondary causes of SFN: abnor-
mal glucose metabolism, large fiber neuropathy, Parkinson dis-
ease, atypical parkinsonism, multiple system atrophy, history of
heavy alcohol exposure, B12 deficiency, folate deficiency, thyroid
disease, hepatitis C, HIV infection, exposure to chemotherapy,
use of neurotoxic medication, cancer, Sjogren syndrome, any
other comorbid condition or use of medication reported to be
associated with SFN. Abnormal glucose metabolism was defined
as hemoglobin A1C, fasting glucose or glucose tolerance test
results indicative of diabetes, prediabetes, or abnormal glucose
tolerance.
Study Inclusion Criteria
The inclusion criteria were (1) patients older than 17 years; (2)
availability of clinical records; (3) completed autonomic testing;
and (3) results of autonomic testing consistent with pure SFN. To
be included in the study, all the inclusion criteria had to be met.
We also collected statin type, dose, duration of treatment, and
cumulative dose. The one dose equivalent was defined as ator-
vastatin 10mg/day, rosuvastatin 5mg/day, lovastatin 40mg/day,
pravastatin 40mg/day, or simvastatin 20mg/day (Anderson et al.,
2005; Wu et al., 2015).
Statistical Analysis
One-way ANOVAwas used to compare the groups with and with-
out statins. The relationships between continuous variables were
obtained using Pearson correlation coefficient (r). All statistical
analyses were performed using JMP 12 (Cary, NC,USA) statistical
software.
Results
From our database we screened 634 participants referred for
evaluation of SFN. One hundred and sixty participants fulfilled
inclusion/exclusion criteria for pure SFN, 80 were treated with
statins (Figure 1). Both on and off statin groups were age and
gender matched. Participant’s characteristics and the effects of
statins are summarized in Table 1.
When comparing statin users with no-users using ANOVA,









FIGURE 1 | Participants’ flow diagram.
TABLE 1 | Characteristics of study participants.
Variable Participants P value
Off statins On statins
Number of participants (f/m) 80 80 1
Age (years) 68:1 9:5 68:1 11:6 0:99
Gender (f/m) 33/47 33/47 1
BMI (kg/m2) 26:9 4:6 26:9 6:1 0:95
Statins Dose equivalent 0 2:5 2:2 N/A
Treatment duration (months) 0 53:5 28:7 N/A
Cumulative dose 0 142:1 169:5 N/A
ENFD-calf (count/mm) 5:9 3:4 4:9 3:2 0:067
ENFD-thigh (count/mm) 10:4 3:8 8:3 3:6 0:0008
SGNFD-calf (count/mm) 41:8 15:9 39:8 15:7 0:426
SGNFD-thigh (count/mm) 56:4 12:7 51:3 14:2 0:018
SCOPA-AUT 15:8 11:6 15:9 14:4 0:93
Pain scale 3:1 1:64 3:1 1:75 0:96
Numbness scale 1:79 0:7 1:75 0:76 0:619
Pain duration (months) 4:4 4:8 4:8 6:1 0:67
Numbness duration (months) 4:9 5:2 4:1 4:6 0:65
QASAT-cardiovagal 1:5 1:0 1:4 1:2 0:578
QASAT-adrenergic failure 4:3 4:3 3:9 3:9 0:52
Means presented as SD.
ENFD, epidermal nerve fiber density; SGNFD, sweat gland nerve fiber density.
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FIGURE 2 | Effect of statins. ENFD, epidermal nerve fiber density; SGNFD, sweat gland nerve fiber density; ns, non-significant. *Significant, p= 0.018 and
**significant, p= 0.0008.
but not at the calf (Table 1; Figure 2). All other comparisons
were not significant. There was no difference in autonomic testing
(QASAT-HRV, QASAT-adrenergic failure) scores between both
groups. There was no significant difference in subjective scales
(pain, numbness, and SCOPA-AUT) between both groups.
Correlation analysis using the Pearson coefficient showed a
significant correlation between the cumulative dose of statins
and thigh ENFD (r= 0.21, p= 0.0065). All other correlations
between the cumulative dose of statins and continuous variables
were not significant. These variables were SGFND at the thigh
(r= 0.11, p= 0.16), SGFND at the calf (r= 0.01, p= 0.88),
ENFD at the calf (r= 0.03, p= 0.65), SCOPA-AUT (r= 0.01,
0.83), the pain scale (r= 0.06, p= 0.54), and the numbness scale
(r= 0.03, p= 0.68).
Discussion
Our main result is the finding of an association between statins
and small nerve fiber degeneration. Statin users had both sensory
and autonomic sudomotor fibers reduced at the thigh. The cumu-
lative statin dose correlated inversely with the sensory fiber den-
sity at the thigh. Furthermore, symptom scales were not affected
by statins. Participants treated with statins did not report more
sensory and autonomic symptoms compared to the statin non-
users.
The proximal, e.g., at the thigh, degeneration of sensory and
autonomic axons with sparing of distal axons indicates a non-
length-dependent process. This pattern can be explained by
simultaneous lesions in the dorsal root ganglia and the autonomic
ganglia causing sensory and autonomic abnormalities, respec-
tively (Sghirlanzoni et al., 2005; Gorson et al., 2008; Gemignani
et al., 2010). Then our findings can be interpreted that statin use
is associated with sensory and autonomic ganglionopathy.
Sensory and autonomic ganglionopathy, also called sensory
and autonomic neuronopathy, although rare, can be associated
with variety of conditions including infection, inflammation,
autoimmunity, critical illness, glucose metabolism abnormalities,
Sjogren syndrome, paraneoplastic, or toxic effects (Satake et al.,
1998; Sumner et al., 2003; Sghirlanzoni et al., 2005; Gorson et al.,
2008; Chai and Logigian, 2010; Gemignani et al., 2010; Koike
and Sobue, 2013; Latronico et al., 2013; Birnbaum and Bingham,
2014). These ganglionopathies are typically acute and associ-
ated with severe neuropathic dysfunction, although subacute and
chronic variants also have been reported. In our cohort, these
conditions were ruled out.
The statin-induced ganglionopathy is most likely mild for sev-
eral reasons. First, sensory and autonomic symptoms were not
different in statin users compared to the non-users even it can even
be argued that sensory symptoms, in general, do not correlate with
duration and severity of SFN (Devigili et al., 2008). Second, the
mean proximal ENFD loss was around 20% and the mean proxi-
mal SGFND loss was around 9% in statin users. Using the QASAT
grading instrument (Novak, 2015), that amount of small fiber loss
is approximately equal to one abnormality range using the normal,
mildly-moderately-severely-markedly abnormal grading system.
Since the baseline fiber density before the onset of statin treatment
is unknown,we can only assumemildworsening of the underlying
fiber density.
There are several possible mechanisms explaining statin-
induced ganglionopathy. The impairment of energy and pro-
tein metabolism, and the induction of necrosis or apoptosis
was associated with statin-induced myopathy (Gaist et al., 2002;
Kiortsis et al., 2007; Lewington et al., 2007; Willey and Elkind,
2010; Millar and Floras, 2014; Argov, 2015). The statin-induced
degeneration of the peripheral ganglia may involve myelin sheath
damage of small myelinated fibers caused by the inhibition of
HMG-CoA reductase, impairing the conversion of HMG-CoA
to mevalonate, which is crucial for the production of cholesterol
(Jones et al., 2014; Norata et al., 2014). Mevalonate is also a
precursor of farnesyl pyrophosphate (FPP), essential for the pro-
duction of ubiquinone and thus, for the production of ATP by the
electron transport chain (Jones et al., 2014; Norata et al., 2014;
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Wilkinson et al., 2014; Patel et al., 2015). FPP depletion can also
impair the production of geranylgeranyl pyrophosphate (Jones
et al., 2014; Norata et al., 2014). Both molecules contribute to the
posttranslational modification of specific intracellular proteins
(such as Rho, Ras, Rab, and nuclear lamins) that if dysfunctional,
can lead to apoptosis (Jones et al., 2014; Norata et al., 2014). In
summary, several mechanisms may underlie the toxic effect of
statins as well as genetic predisposition.
There are several shortcomings of our study. The study has
retrospective character, various doses of statins among partici-
pants, use of particular type statins, and other biases. Therefore,
it is possible that our study was not sensitive enough to detect a
symptomatic effect of statins. Furthermore, we did not evaluate
markers of abnormal glucose metabolism, the most common
cause of the SFN (Hovaguimian and Gibbons, 2011), although we
did exclude patients with history of abnormal glucosemetabolism.
Nevertheless, abnormal glucose metabolism is usually associated
with the length-dependent (distal) SFN (Polydefkis et al., 2003;
Hovaguimian and Gibbons, 2011) and not with the non-length-
dependent pattern that was observed in our study. Hence, it is
unlikely that abnormal glucose metabolism contributed to our
results.
In conclusion, our study indicates that statins have neuropathic
effects. The distribution of abnormalities and the severity of symp-
toms aremost consistent withmild, likely subclinical, sensory, and
autonomic ganglionopathy.
Author Contributions
PN and LQ collected data. PN and VN were responsible for
statistical analysis. PNwrote the first draft of the paper. All authors
reviewed the study findings, the paper and approved the paper. PN
performed statistical analysis.
Funding
The study was funded by Department of Neurology, University of
Massachusetts Medical School, Worcester, MA, USA. The authors
thank Shane Stanek and Steve Smajkiewicz for their help in data
collection.
References
Anderson, J. L., Muhlestein, J. B., Bair, T. L., Morris, S., Weaver, A. N., and Lappé,
D. L. (2005). Do statins increase the risk of idiopathic polyneuropathy? Am.
J. Cardiol. 95, 1097–1099. doi:10.1016/j.amjcard.2004.12.068
Argov, Z. (2015). Statins and the neuromuscular system: a neurologist’s perspective.
Eur. J. Neurol. 22, 31–36. doi:10.1111/ene.12604
Birnbaum, J., and Bingham, C. O. III (2014). Non-length-dependent and length-
dependent small-fiber neuropathies associated with tumor necrosis factor
(TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the
spectrum of neurological disease associated with TNF-inhibitors. Semin. Arthri-
tis Rheum. 43, 638–647. doi:10.1016/j.semarthrit.2013.10.007
Boger, M. S., Hulgan, T., Donofrio, P., and Peltier, A. C. (2011). QSART for
diagnosis of statin-associated polyneuropathy. Muscle Nerve 43, 295–296. doi:
10.1002/mus.21906
Chai, J., and Logigian, E. L. (2010). Neurological manifestations of primary
Sjogren’s syndrome. Curr. Opin. Neurol. 23, 509–513. doi:10.1097/WCO.
0b013e32833de6ab
Cook, K. F., Dunn, W., Griffith, J. W., Morrison, M. T., Tanquary, J., and Sabata,
D. (2013). Pain assessment using the NIH Toolbox. Neurology 80(11 Suppl. 3),
S49–S53. doi:10.1212/WNL.0b013e3182872e80
Devigili, G., Tugnoli, V., Penza, P., Camozzi, F., Lombardi, R., and Melli, G.
(2008). The diagnostic criteria for small fiber neuropathy; from symptoms of
neuropathology. Brain 131, 1912–1925. doi:10.1093/brain/awn093
Gaist, D., Jeppesen, U., Andersen, M., García Rodríguez, L. A., Hallas, J., and
Sindrup, S. H. (2002). Statins and risk of polyneuropathy: a case-control study.
Neurology 58, 1333–1337. doi:10.1212/WNL.58.9.1333
Gemignani, F., Giovanelli, M., Vitetta, F., Santilli, D., Bellanova, M. F., and Brin-
dani, F. (2010). Non-length dependent small fiber neuropathy. a prospective
case series. J. Peripher. Nerv. Syst. 15, 57–62. doi:10.1111/j.1529-8027.2010.
00252.x
Gibbons, C. H., Illigens, B.M.W.,Wang, N., and Freeman, R. (2009). Quantification
of sweat gland innervation: a clinical-pathologic correlation. Neurology 72,
1479–1486. doi:10.1212/WNL.0b013e3181a2e8b8
Gorson, K. C., Herrmann, D. N., Thiagarajan, R., Brannagan, T. H., Chin, R.
L., and Kinsella, L. J. (2008). Non-length dependent small fibre neuropa-
thy/ganglionopathy. J. Neurol. Neurosurg. Psychiatry 79, 163–169. doi:10.1136/
jnnp.2007.128801
Hernández-Ojeda, J., Román-Pintos, L. M., Rodríguez-Carrízalez, A. D., Troyo-
Sanromán, R., Cardona-Muñoz, E. G., and Alatorre-Carranza Mdel, P. (2014).
Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind,
placebo-controlled Phase IIa study. Diabetes Metab. Syndr. Obes. 7, 401–407.
doi:10.2147/DMSO.S65500
Hovaguimian, A., and Gibbons, C. H. (2011). Diagnosis and treatment of pain in
small fiber neuropathy. Curr. Pain Headache Rep. 15, 193–200. doi:10.1007/
s11916-011-0181-7
Jones, J. D., Kirsch, H. L., Wortmann, R. L., and Pillinger, M. H. (2014). The
causes of drug-induced muscle toxicity. Curr. Opin. Rheumatol. 26, 697–703.
doi:10.1097/BOR.0000000000000108
Kiortsis, D. N., Filippatos, T. D., Mikhailidis, D. P., Elisaf, M. S., and Liberopoulos,
E. N. (2007). Statin-associated adverse effects beyond muscle and liver toxicity.
Atherosclerosis 195, 7–16. doi:10.1016/j.atherosclerosis.2006.10.001
Koike, H., and Sobue, G. (2013). Autoimmune autonomic ganglionopathy and
acute autonomic and sensory neuropathy. Rinsho Shinkeigaku 53, 1326–1329.
doi:10.5692/clinicalneurol.53.1326
Latronico, N., Filosto, M., Fagoni, N., Gheza, L., Guarneri, B., and Todeschini,
A. (2013). Small nerve fiber pathology in critical illness. PLoS ONE 8:e75696.
doi:10.1371/journal.pone.0075696
Lauria, G., Hsieh, S. T., Johansson, O., Kennedy, W. R., Leger, J. M., Mellgren, S.
I., et al. (2010). European federation of neurological societies/peripheral nerve
society guideline on the use of skin biopsy in the diagnosis of small fiber
neuropathy. Report of a joint task force of the European federation of neuro-
logical societies and the peripheral nerve society. Eur. J. Neurol. 17, 903–949.
doi:10.1111/j.1468-1331.2010.03023.x
Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J., Qizilbash, N.,
et al. (2007). Blood cholesterol and vascular mortality by age, sex, and blood
pressure: a meta-analysis of individual data from 61 prospective studies with
55,000 vascular deaths. Lancet 370, 1829–1839. doi:10.1016/S0140-6736(07)
61778-4
Lo, L. Y., Leoh, T. H., Loh, L. M., and Tan, C. E. (2003). Statin therapy and small
fiber neuropathy: a serial electrophysiological study. J. Neurol. Sci. 208, 105–108.
doi:10.1016/S0022-510X(02)00396-9
Low, V. A., Sandroni, P., Fealey, R. D., and Low, P. A. (2006). Detection of small-
fiber neuropathy by sudomotor testing. Muscle Nerve 34, 57–61. doi:10.1002/
mus.20551
McArthur, J. C., Stocks, E. A., Hauer, P., Cornblath, D. R., and Griffin, J.
W. (1998). Epidermal nerve fiber density: normative reference range and
diagnostic efficiency. Arch. Neurol. 55, 1513–1520. doi:10.1001/archneur.55.12.
1513
Millar, P. J., and Floras, J. S. (2014). Statins and the autonomic nervous system. Clin.
Sci. 126, 401–415. doi:10.1042/CS20130332
Norata, G. D., Tibolla, G., and Catapano, A. L. (2014). Statins and skeletal muscles
toxicity: from clinical trials to everyday practice. Pharmacol. Res. 88, 107–113.
doi:10.1016/j.phrs.2014.04.012
Novak, P. (2011). Quantitative autonomic testing. J. Vis. Exp. 53, e2502. doi:10.3791/
2502
Frontiers in Aging Neuroscience | www.frontiersin.org October 2015 | Volume 7 | Article 1915
Novak et al. Statins and ganglionopathy
Novak, P. (2015). Quantitative scale for grading of cardiovascular autonomic reflex
tests and small fibers from skin biopsies. J. Neurol. Dis. 3, 226. doi:10.4172/2329-
6895.1000226
Novak, V., Freimer, M. L., Kissel, J. T., Shahenk, Z., Periquet, I. M., and Nash, S. M.
(2001). Autonomic impairment in painful neuropathy. Neurology 56, 861–868.
doi:10.1212/WNL.56.7.861
Patel, J., Superko, H. R., Martin, S. S., Blumenthal, R. S., and Christopher-Stine,
L. (2015). Genetic and immunologic susceptibility to statin-related myopathy.
Atherosclerosis 240, 260–271. doi:10.1016/j.atherosclerosis.2015.03.025
Polydefkis, M., Griffin, J. W., and McArthur, J. (2003). New insights into diabetic
polyneuropathy. JAMA 290, 1371–1376. doi:10.1001/jama.290.10.1371
Satake, M., Nakagawa, Y., Yamashita, S., Hashiguchi, E., Fujii, N., and Yoshimura,
T. (1998). Subacute autonomic and sensory ganglionopathy: a postmortem case.
J. Neurol. Neurosurg. Psychiatry 64, 561. doi:10.1136/jnnp.64.4.561
Sghirlanzoni, A., Pareyson, D., and Lauria, G. (2005). Sensory neuron diseases.
Lancet Neurol. 4, 349–361. doi:10.1016/S1474-4422(05)70096-X
Sumner, C. J., Sheth, S., Griffin, J. W., Cornblath, D. R., and Polydefkis, M.
(2003). The spectrum of neuropathy in diabetes and impaired glucose tolerance.
Neurology 60, 108–111. doi:10.1212/WNL.60.1.108
Visser, M., Marinus, J., Stiggelbout, A. M., and Van Hilten, J. J. (2004). Assessment
of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT.Mov. Disord.
19, 1306–1312. doi:10.1002/mds.20153
Wilkinson, M. J., Laffin, L. J., and Davidson, M. H. (2014). Overcoming toxicity and
side-effects of lipid-lowering therapies. Best Pract. Res. Clin. Endocrinol. Metab.
28, 439–452. doi:10.1016/j.beem.2014.01.006
Willey, J. Z., and Elkind, M. S. (2010). 3-Hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitors in the treatment of central nervous system diseases. Arch.
Neurol. 67, 1062–1067. doi:10.1001/archneurol.2010.199
Wu, C. K., Yang, Y. H., Lin, T. T., Tsai, C. T., Hwang, J. J., and Lin, J. L. (2015).
Statin use reduces the risk of dementia in elderly patients: a nationwide data
survey and propensity analysis. J. Intern. Med. 277, 343–352. doi:10.1111/joim.
12262
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Novak, Pimentel, Sundar, Moonis, Qin and Novak. This is an open-
access article distributed under the terms of the Creative CommonsAttribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org October 2015 | Volume 7 | Article 1916
